LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Reportedly Prepares €15 Billion Bid for French Biotech Abivax
Eli Lilly is reportedly preparing a €15 billion offer to acquire French biotechnology firm Abivax. The U.S. pharmaceutical giant has not yet submitted a formal...
Eli Lilly's Taltz and Zepbound Combination Therapy Succeeds in Phase 3b Psoriatic Arthritis Trial
Eli Lilly released positive topline results from the Phase IIIb TOGETHER-PsA study. The trial combined the arthritis drug Taltz (ixekizumab) with the...
Eli Lilly shares little changed in pre-market as Zacks names it 'Bull of the Day'
Eli Lilly shares are trading modestly higher pre-market at $1088.85 after Zacks Equity Research selected the company as its “Bull of the Day,” emphasizing its...
Eli Lilly shares little changed as insider sale and obesity-pill optimism balance out
Eli Lilly received a significant boost after UBS raised its price target to $1,250, maintaining a bullish outlook on the company's robust obesity pipeline,...
Eli Lilly shares little changed in after-hours trading ahead of January 9 session
A recent Form 4 filing revealed that Lilly Endowment Inc. executed a significant insider sale on January 7, offloading 293,446 shares of Eli Lilly for...
Eli Lilly Expands AI Drug Discovery and Immunology Pipeline with New Collaboration and Potential Acquisition
Eli Lilly and Company announced a collaboration with BigHat Biosciences to advance its machine-learning biologics discovery platform, TuneLab. BigHat will...
Eli Lilly Announces Major Obesity Drug Partnership and Is in Talks for $1B+ Acquisition, Fueling Stock Surge
Eli Lilly and Company stock surged on January 7, 2026. The rise followed two major announcements bolstering its position in the high-growth obesity drug...
🟢 LLY is trading 3.7% up today on reports of $1B+ Ventyx Biosciences acquisition talks
LLY is trading at $1103.03 (+3.7%) amid reports of advanced talks to acquire Ventyx Biosciences for over $1 billion. * Ventyx's experimental pills target...
Eli Lilly Expands Obesity Pipeline with $1.3B Nimbus Therapeutics Collaboration
Eli Lilly and Company announced a multi-year collaboration with Nimbus Therapeutics. The partnership focuses on developing a novel preclinical oral obesity...
Eli Lilly Slashes Mounjaro Price in China by Nearly 70%
Eli Lilly drastically cut the price of its weight-loss drug, Mounjaro, in the Chinese market. The monthly cost for the lowest dose fell nearly 70%. The price...
Indiana Sues Eli Lilly Over Alleged Insulin Price-Fixing Scheme
Indiana Attorney General Todd Rokita filed a new lawsuit against Eli Lilly on December 31, 2025, alleging an insulin price-fixing scheme. The lawsuit claims...
🔴 LLY is trading 3% down today as rival Novo Nordisk begins selling obesity pill in U.S.
LLY is trading at $1045.85 (-3.19%) following reports of a 4% drop linked to competitor Novo Nordisk launching its obesity pill in the U.S., intensifying...
Eli Lilly Anticipates Key Readouts for Obesity and Alzheimer's Drugs in H1 2026
Eli Lilly faces a significant period in the first half of 2026, driven by two major clinical milestones. Both events are scheduled for March. The first...
Eli Lilly Sees Certain Fraud Claims Trimmed in Insulin-Pricing Lawsuit
The U.S. District Court for the District of New Jersey dismissed certain civil fraud claims against Eli Lilly & Co. and other drugmakers. The claims related to...
Eli Lilly and Boehringer Ingelheim to Cut Jardiance Price by Over 40%
Eli Lilly and partner Boehringer Ingelheim will cut the U.S. list price of the diabetes drug Jardiance and related treatments. The reduction exceeds 40%. This...
Eli Lilly and Partner Vanda Pharmaceuticals Gain FDA Approval for Novel Motion Sickness Drug
Eli Lilly and Vanda Pharmaceuticals secured FDA approval for Nereus (tradipitant). The drug is indicated for the prevention of vomiting induced by...
Eli Lilly Slashes Mounjaro Prices in China Amidst Growing Competition
Eli Lilly and Company implemented a significant price reduction for its popular weight-loss drug, Mounjaro, in the Chinese market. Reports citing Chinese drug...
Eli Lilly Faces Enhanced Oral Weight-Loss Competition as Novo Nordisk Secures First FDA Approval
Novo Nordisk secured U.S. FDA approval for its oral Wegovy on December 23, positioning it as the first oral weight-loss GLP-1 drug on the market. This...
Eli Lilly's Potential Abivax Takeover Speculation Intensifies
Speculation regarding a potential takeover of French biotech Abivax by Eli Lilly intensified on December 22, 2025. Fresh reports allege that Eli Lilly...
🟢 LLY is trading 3% up today on positive Phase 3 data for oral drug orforglipron
LLY is trading at +3.06% now at $1073.65 following the announcement of positive Phase 3 trial results for its oral weight-loss drug, orforglipron. * The...